About this episode
Join Prof Iain McInnes as he reviews two interesting papers. The first covers the impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis. The second discusses infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Get every episode summarized
Each time The IMID Forum publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The IMID Forum
Author Interview: Doctor Elise van Mulligen, September 2026
The IMID Forum
Sep 3, 202621:20pending
Discussing RA: Biologic effectiveness and treatment persistence in RA
The IMID Forum
Aug 27, 20268:52pending
Discussing PsA: Advances in Psoriatic Arthritis Management and Treatment Safety
The IMID Forum
Aug 20, 202624:22pending
Author Interview: Professor Axel Finckh and Associate Professor Bente Glintborg,...
The IMID Forum
Aug 13, 202626:58pending